Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: Two-year results of a prospective, randomized multicenter trial

Medicine and Dentistry

• Acute Graft Rejection 10%
• Adverse Event 5%
• Alemtuzumab 21%
• Belatacept 100%
• Biopsy Sample 10%
• Calcineurin 5%
• Calcineurin Inhibitor 100%
• Clinical Trial 5%
• Corticosteroid 100%
• Death 5%
• Graft Survival 5%
• Immunosuppressive Treatment 100%
• Incidence 10%
• Kidney Allograft 5%
• Kidney Graft 10%
• Kidney Transplantation 5%
• Measurement 5%
• Nephrotoxicity 5%
• Patient 5%
• Randomized Clinical Trial 5%
• Steroid 21%
• Survival Rate 5%
• T Cell 5%
• Tacrolimus 57%
• Thymocyte Antibody 78%
• Toxicity 5%

Immunology and Microbiology

• Acute Graft Rejection 10%
• Alemtuzumab 21%
• Allotransplantation 5%
• Anti-Thymocyte Globulin 78%
• Belatacept 100%
• CD28 5%
• Immunosuppression 100%
• Immunosuppressive Therapy 5%
• Incidence 10%
• Kidney 15%
• Kidney Transplantation 5%
• Leporidae 78%
• Sample 10%
• Survival Rate 5%
• T Cell 5%
• Tacrolimus 57%
• Transplantation 10%